Cryoablation + Immunotherapy

Note: This page is educational and reflects the state of the literature in 2025. It does not replace medical advice.

TL;DR

Cryoablation kills tumor tissue with extreme cold via percutaneous probes — a minimally invasive alternative to surgery for selected cancers. Beyond local destruction, freezing releases tumor antigens and DAMPs in an inflammatory milieu and can prime a systemic anti-tumor immune response. The combination with immune checkpoint inhibitors seeks to convert this local effect into systemic tumor control (the long-pursued abscopal effect). Approved/used as standalone therapy in selected breast, kidney, prostate, lung, and bone-metastasis indications; the immunotherapy combination is mostly investigational in 2024–2025.
Sources: [1]

1. What cryoablation does

A cryoprobe inserted under image guidance (US, CT, MRI) creates a freeze–thaw–freeze cycle that:
Sources: [1]

Lowers tissue to −20 to −40 °C → ice crystal formation, osmotic stress, vascular collapse.
Direct cell death by membrane rupture.
Vascular thrombosis in the freeze zone.
Antigen release as the cells lyse — including potentially tumor-specific neoantigens.
DAMPs (damage-associated molecular patterns) — HMGB1, ATP, HSPs — that activate dendritic cells.

The treatment is precise: the "ice ball" can be visualized in real time on imaging, and surrounding healthy tissue is largely spared. Recovery is rapid; many cases are outpatient.

2. Why pair it with immunotherapy

Standalone cryoablation usually controls only the tumor it touches. The abscopal effect — regression of distant, untreated metastases after a local intervention — has been observed sporadically since the 1950s but remains rare with monotherapy.
Sources: [1]

The hypothesis pursued in 2024–2025 trials:

Cryo (antigen release + DAMPs)
        +
Anti-PD-1 / anti-PD-L1 / anti-CTLA-4 (checkpoint release)
        ↓
Systemic anti-tumor T-cell response
        ↓
Distant tumor regression (abscopal)

This is conceptually parallel to the rationale for radiotherapy + immunotherapy and oncolytic-virus + checkpoint combinations.
Sources: [1]

3. Clinical landscape

Indication	Cryoablation alone	Cryo + IO
Small renal masses	Standard alternative to partial nephrectomy in selected cases	Investigational
Bone metastasis (palliation)	FDA-cleared for pain	Some trials
Breast (small T1, low risk)	Used in selected centers, especially as alternative to surgery in elderly	Active trials in advanced or metastatic disease
Prostate (focal)	Established in some health systems	Mostly investigational
Lung (small T1, inoperable)	Used as ablative alternative to SBRT	Active trials
Liver tumors	Used; competes with RFA / microwave / histotripsy	Investigational
Selected metastatic melanoma, sarcoma	Salvage / oligometastatic	Active trials with IO

T-VEC and HIFU ablation pursue similar combinational logic with different physics (Acoustic tumor therapy, Oncolytic virus therapy).

4. What we actually know about the abscopal/immune effect

Honest read of the 2022–2025 literature:
Sources: [1]

Mechanism is biologically plausible and supported by preclinical models.
Case reports and small case series of dramatic abscopal responses exist.
Randomized data are limited. Most trials are Phase I/II, single-arm, or small.
Patient selection matters — tumor type, immune microenvironment, and prior IO exposure all influence whether the combination "wakes up" systemic immunity.
Timing matters — sequence of cryo and IO, dose, and ablation volume all under investigation.

The honest framing: cryo + IO is promising but unproven outside selected indications. It should not be presented as standard of care for systemic disease.
Sources: [1]

5. Strengths and limits

Strengths

Minimally invasive, image-guided, repeatable.
Tissue is destroyed in situ — antigens stay local for immune presentation, unlike thermal ablation which denatures some.
Combinable with IO, chemo, radiation.
Feasible in elderly and frail patients.

Limits

Tumor size and location matter — large or deep targets are harder.
Skin and adjacent organs need protection (hydro- or air-dissection).
Most data come from single-arm series; randomized trials sparse.
Insurance/SUS coverage uneven.
Operator skill matters — outcome variability across centers.

6. What technologists can build

Image-guided treatment planning — segment tumor, predict ice-ball coverage, optimize probe placement.
Real-time monitoring — multi-modal (CT, MR thermometry, US elastography) fusion.
Outcome registries — link procedural detail (probe count, ice-ball size, freeze-thaw cycles) to long-term outcome and immune response.
Combination optimization — predict which patients will benefit from cryo + IO from baseline tumor immunology.
Wearable post-procedure monitoring — early detection of immune-related adverse events.

7. Brazilian context

Cryoablation is performed in selected interventional-radiology services in private oncology in Brazil; less common in SUS.
Trials combining cryo with checkpoint inhibitors typically occur in larger academic-private centers (A.C. Camargo, Sírio-Libanês, Albert Einstein, ICESP, Hospital Moinhos de Vento).
Equipment cost and probe consumables are major barriers to wider adoption.

References

Olagunju A, Forsman T, Ward RC. An update on the use of cryoablation and immunotherapy for breast cancer. Front Immunol 2022;13:1026475. PMID 36389815. https://doi.org/10.3389/fimmu.2022.1026475
U.S. National Cancer Institute. https://www.cancer.gov/about-cancer/understanding/what-is-cancer
American Cancer Society. https://www.cancer.org/cancer.html
Cleveland Clinic. Cancer (overview). https://my.clevelandclinic.org/health/diseases/12194-cancer
A.C. Camargo Cancer Center. https://accamargo.org.br
Fundação do Câncer (Brasil). https://www.cancer.org.br/
Ministério da Saúde / BVS. ABC do câncer. https://bvsms.saude.gov.br/bvs/publicacoes/abc_do_cancer.pdf
ANVISA. https://www.gov.br/anvisa/pt-br

PubMed citations retrieved via NCBI E-utilities.

Cryoablation + Immunotherapy ​

TL;DR ​

1. What cryoablation does ​

2. Why pair it with immunotherapy ​

3. Clinical landscape ​

4. What we actually know about the abscopal/immune effect ​

5. Strengths and limits ​

6. What technologists can build ​

7. Brazilian context ​

See also ​

References ​